DOI: https://doi.org/10.29296/25877313-2018-03-07
Download full text PDF

A.V. Malinovsky Engineer-technologist, «Biofizpribor», Branch of Federal Medical-Biological Agency (Saint Petersburg) E-mail: info@biofizpribor.ru

As is known, in rats the administration of L-threonine leads to the increase of glycine level in the brain and spinal cord. Therefore, in two world famous clinics they decided to use L-threonine in the treatment of patients with spasticity to see whether in the brain and spinal cord of man it also transforms to glycine. However, L-threonine at the taken doses gave no effect, neither was changed the level of glycine in the cerebrospinal fluid. In the present paper it is pointed out that in the process of evolution the man, on the genetic level, lost the ability to synthesize L- threonine 3-dehydrogenase, the enzyme, present in many animals, which might be involved in transformation of L-threonine to glycine.This makes possible to fight such parasites of man as trypanosomes,which cause sleeping sickness,using L-threonine 3-dehydrogenase from them as a target of therapeutic treatment.In other words,in trypanosomes L-threonine 3-dehydrogenase has an important role in enzyme metabolism,its inhibition by a wide range of sulphydryl reagents leads to a loss of the vitial capacity of trypanosomes cousing no damage to man. The conclusion is made that L-threonine is not to be used against spasticity.


It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

  1. Wurtman R.J. L-threonine for regulating glycine levels in the brain and spinal cord. European patent specification. 1986. Publication Number: 0 028 257 B1.
  2. D’Mello J.P.F. Aspects of threonine and glycine metabolism in the chick (Gallus domesticus) // J. Nutr. 1973. V. 15. № 6. P. 357−363.57 B1.
  3. Growdon J.H., Nader T.M., Schoenfeld J., Wurtman R.J. Lthreonine in the treatment of spasticity // Cln. Neuropharm. 1991. V. 14. № 5. R. 403−412.
  4. Lee A., Patterson V. Double-blind study of L-threonine in patients with spinal spasticity // Acta Neurol. Scand. 1993. № 88. R. 334−338.
  5. Degli S., Nikol'son D. Metabolicheskie puti. M.: Mir. 1973 (Djegli S., Nikol’son D. Metabolicheskie puti. M.: Mir. 1973).
  6. Neuberger A. Glycine formation from L-threonine // Comp. Biochem. 1981. V. 19A. P. 257−303.
  7. Bird M.I., Nunn P.B. Measurement of L-threonine aldolase activity in rat liver // Biochem. Soc. Trans. 1979. V. 7. P. 1274–1276.
  8. Yeung, Y.G. Threonine aldolase is not a genuine enzyme in rat liver // Biochem J. 1986. V. 237. P. 187–190.
  9. Pagani R. L-allothreonine and L-threonine aldolase in rat liver // Biochem. Soc. Trans. 1991. V. 19. № 3. P. 3465.
  10. Darling P.B., Grunov J., Rafii M., Brookes S., Ball R.O., Pencharz P.B. Threonine dehydrogenase is a minor degratative pathway of threonine catabolism in adult humans. Am. J. Physiol. Endocrinol. Metab. 2000. V. 278. R. 877−884.
  11. Schirch I., Gross T. Serine transhydroxymethylase Identification as the threonine and allothreonine aldolases. J. Biol. Chem. 1968. № 243. R. 5651−5655.
  12. Ogawa H., Gomi T., Fujioka M. Serine hydroxymethyltransferase and threonine aldolase: are they identical? // The International Journal of Biochemistry and Cell Biology. 2000. № 32. R. 289−301.
  13. Zhao X.H., Wen Z.M., Meredith C.N., Matthews D.E., Bier D.M., Young V.R. Threonine kinetics at graded threonine intakes in young men // Am. J. Cln. Nutr. 1986. № 43. R. 795−798.
  14. Edgar A.J. The human L-threonine-3-dehydrogenase gene is an expressed pseudogene // BMC Biochem. 2002. V. 18. № 3.
  15. Chuanchin H., Hao G., Jiaxu W., Weiguang L., Yide M., Mian W. Regulation of L-threonine dehydrogenase in somatic cell reprogramming // Stem. Cells. 2013. № 31. R. 953−965.
  16. Winkle L.J.V., Gallet V., Iannaccone P.M. Threonine appears to be essential for proliferation of human as well as mouse embryonic stem cells // Cells and developmental biology. 2014. May 2. Article 18/1.